Allocate Software

Press: Allocate Software rose on record annual results prompting Numis to raise its target price to 100p and upgrade 2012 earnings forecast by... read more

Press: Allocate Software rose on record annual results prompting Numis to raise its target price to 100p and upgrade 2012 earnings forecast by GBP0.2m to GBP6.3m. Earnings last year jumped 57pc to GBP5.8m on a 37pc gain in revenues to GBP30.1m. Healthcare revenue increased by 56pc to GBP23.1m. The broker says the shares remain far too cheap for the growth and long term potential. Source - Mail

Press: Allocate Software was unchanged after announcing its sixth acquisition in three years. It has bought Zircadian, the UK-based provider of... read more

Press: Allocate Software was unchanged after announcing its sixth acquisition in three years. It has bought Zircadian, the UK-based provider of software used to plan the rotas of junior doctors and consultants in the NHS, for up to GBP7million. Its products are used by 142 healthcare groups in the UK. Broker Numis has a target price of 98p and says Allocate is very cheap for its market position. Source - Mail

Numis raises its recommendation from ?hold? to ?buy? after a "robust Q4 trading update". It left its price target for the stock... read more

Numis raises its recommendation from ?hold? to ?buy? after a "robust Q4 trading update". It left its price target for the stock unchanged at 96 pence. Analyst David Toms said "Management expects FY11 results to be in line with expectations, and consequently we leave our forecasts unchanged. As has been Allocate?s practice, the Q4 trading update does not contain any outlook statement for FY12, but we believe that management remains confident in the group?s prospects and comfortable with market expectations."

Analyst: Allocate Software has complemented organic expansion with targeted acquisitions to build a solid platform for growth through both cross... read more

Analyst: Allocate Software has complemented organic expansion with targeted acquisitions to build a solid platform for growth through both cross selling and international expansion. Financial performance has been strong, while a growing contribution of overseas and recurring revenues should add robustness to the financial profile. Given the considerable scope for growth, neither our estimates nor the rating look demanding - INDUSTRY OUTLOOK - Allocate reports still seeing a strong pipeline into the NHS, which stands testament to the rapid ROI of Healthroster and the ability to cross-sell. Dynamic Change (acquired in May) is being more adversely impacted due to the dissolution of the PCTs. However, the overseas opportunity has really started to crystallise over the past year or so, giving the business the potential to scale up significantly. Source: edisoninvestmentresearch.co.uk